hg3 cll cell lines  (DSMZ)

Journal: Scientific Reports

Article Title: Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

doi: 10.1038/s41598-020-78315-0

Figure Lengend Snippet: Compound library screening in HG3 and HS-5 cell lines. ( A ) Viability of cells treated with the compounds at the concentration of 15 µM in the HG3 and HS-5 cell lines. ( B ) Cytotoxicity of the compounds at 15 µM concentration in HG3 alone and in coculture with HS-5. ( C ) Heat maps showing viability of cells treated with the selected compounds (A12, A2, A1, F1, D1, C11, C7,C6) at the concentrations of 1–5–15 µM in the HG3 and HS-5 cell lines. ( D ) Heat maps showing cytotoxicity of the selected compounds (A12, A2, A1, F1, D1, C11, C7,C6) at the doses of 1–5–15 µM in HG3, HG3 in coculture with HS-5 and in HS-5. Cells were treated for 48 h with the compounds at concentrations from 1 to 15 µM. Each dot ( A , B ) and each box ( C , D ) represent the mean of 3 independent experiments. Dotted line in ( A , B ) indicates the threshold to discriminate the effect of the compounds. The cut off for MTT and cytotoxicity was 50% and 20%, respectively. Viability of CLL cells was measured using the MTT assay, and is depicted relative to untreated control. Cytotoxicity was defined as the increase in Annexin-V+/PI + cells compared to untreated control.

Article Snippet: We used the CLL cell lines HG3 (ACC 765) and MEC-1 (ACC 497) from the German Collection of Microorganisms and Cell Cultures (DSMZ) and the human bone-marrow derived stromal cell line HS-5 (CRL-11882) from the American Type Culture Collection (ATCC).

Techniques: Drug discovery, Concentration Assay, MTT Assay, Control

Journal: Scientific Reports

Article Title: Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

doi: 10.1038/s41598-020-78315-0

Figure Lengend Snippet: Validation of selected targets. Cells were treated for 48 h with the compounds at concentrations from 1 to 15 µM. Each dot represents the mean of 3 independent experiments. Dotted line indicates the threshold to discriminate the effect of the compounds. The cut off for MTT and cytotoxicity was 50% and 20% respectively. Viability of CLL cells was measured using the MTT assay and is depicted relative to untreated control. Cytotoxicity was defined as the increase in Annexin-V +/PI+ cells compared to untreated control. ( A ) Viability of cells treated with A1, A12, C5 and C7 and NOD1/2 specific inhibitors in HG3, MEC1 and HS-5 cell lines. ( B ) Cytotoxicity of A1, A12, C5 and C7 and NOD1/2 specific inhibitors in HG3, HG3 in coculture with HS-5 and in HS-5 cells. ( C ) Viability of cells treated with the F1 compound (simvastatin) and different statins and specific LFA-1 inhibitors in the HG3, MEC and HS-5 cell lines. ( D ) Cytotoxicity of F1 compound and different statins and specific LFA-1 inhibitors in HG3 alone, HG3 in coculture with HS-5 and in HS-5 alone. Round dots: compounds that target NOD1/2; Square dots: compounds that target HMGCR and LFA-1; Grey dots: specific inhibitors for each target. ( E ) Schematic description of statins mechanism of action.

Article Snippet: We used the CLL cell lines HG3 (ACC 765) and MEC-1 (ACC 497) from the German Collection of Microorganisms and Cell Cultures (DSMZ) and the human bone-marrow derived stromal cell line HS-5 (CRL-11882) from the American Type Culture Collection (ATCC).

Techniques: Biomarker Discovery, MTT Assay, Control

Journal: Scientific Reports

Article Title: Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

doi: 10.1038/s41598-020-78315-0

Figure Lengend Snippet: Statins reduce CLL migration, proliferation and viability. Cells were treated for 48 h with the compounds at concentrations of 1 µM. ( A ) Cell phase object confluence after F1 treatment which was monitored for 48 h by recording phase images using the IncuCyte Live Cell Analysis Imaging System in HG3, HS-5 and coculture of HG3 and HS5 cells (n = 3). Bars represent the ± SD of all samples analyzed. ( B ) CXCL12-induced adhesion/migration of CLL cells treated with statins or LFA-1 inhibitors for 3 h and analyzed by transwell assays. Values are presented as the ratio of migrating cells and total viable cells, relative to the untreated control. Dotted line indicates the untreated control reference. ( C ) CXCL13-induced adhesion/migration of CLL cells treated with statins or LFA-1 inhibitors for 3 h and analyzed by transwell assays. Values are presented as the ratio of migrating cells and total viable cells, relative to the untreated control. Dotted line indicates the untreated control reference. ( D ) Percentage of proliferating CD19 + CLL cells after ODN2006 + IL15 (ODN IL15) stimulation (30 min before treatment) and treatment with different drugs for 6 days measured by CFSE dilution (n = 7). ( E ) Flow cytometry histograms of a CLL representative case (#4) show the percentages of proliferating cells (gated on viable CD19+ cells) after 6 days of ODN2006 + IL15 stimulation. A decrease in CFSE signal is indicative of cells that have divided. FMO, fluorescence-minus-one. Non-parametric Wilcoxon matched-pairs signed rank test was used for statistical analysis. *P < 0.05. Lov: lovastatin, Fluv: fluvastatin, Rosu: rosuvastatin, Lifi: lifitegrast and B033: BDBM50199033B033.

Article Snippet: We used the CLL cell lines HG3 (ACC 765) and MEC-1 (ACC 497) from the German Collection of Microorganisms and Cell Cultures (DSMZ) and the human bone-marrow derived stromal cell line HS-5 (CRL-11882) from the American Type Culture Collection (ATCC).

Techniques: Migration, Live Cell Imaging, Control, Flow Cytometry, Fluorescence